Company profilePharmaceutical#448 of 1,318 in Pakistan✓ No DRAP alerts

AL-HABIB PHARMACEUTICALS.

Pharmaceutical company · 34 brands · 33 molecules

Ranked #2 of 44 companies in Antineoplastics

34 registered products 14 pharmaceutical brands 33 distinct molecules 0 DRAP alerts

Company overview

34
registered products
14
pharmaceutical brands
33
distinct molecules
8
therapeutic classes
0
DRAP alerts

AL-HABIB PHARMACEUTICALS. is a pharmaceutical manufacturer registered with the Drug Regulatory Authority of Pakistan, holding 34 product registrations across 33 distinct molecules. Its portfolio is concentrated in Antineoplastics and Other Beta-Lactam, Cephalosporins & Penems. It has no DRAP recall, shortage or safety notices on record.

Compiled from the DRAP registry, DRAP approved prices and DRAP alerts, with observed retail from DVAGO and Servaid. Data as of 2026-07-30.

Products by AL-HABIB

1 product matched in our catalogue — each with its observed price and DRAP approved ceiling.

Antineoplastics 1

Top molecules by brand count

Ceftriaxone2 brands
Citalopram2 brands
Idarubicin1 brand
Etoposide1 brand
Bleomycin1 brand
Paclitaxel1 brand

Therapeutic classes

Antineoplastics · 17Other Beta-Lactam, Cephalosporins & Penems · 1Drugs For Peptic Ulcer And Gastro-Oesophageal Reflux Disease (Gord) · 1Immunosuppressants · 1Diagnostic Agents · 1All Other Therapeutic Products, Antidotes · 1Endocrine Hormone Therapy · 1Vitamin B12 Plain · 1

Price band (DRAP official ceilings)

Registered products priced by source
DVAGO1 products · Rs 1,062 – Rs 1,062
Median across source: Rs 1,062

Regulatory record

No DRAP alerts on record

No recalls, shortage notices or safety alerts involving this company’s products appear in the DRAP alert feed we track. Median across all 1,318 mapped companies is zero — 1,165 of them also have a clean sheet.

Competitive set

Companies whose registered portfolio overlaps most with this one.

Portfolio whitespace

Molecules the closest competitors have registered and this company has not — the starting point for a launch shortlist.

Pharmedic Pharmaceuticals Industries (Pvt.) Ltd. holds 92 molecules not in this portfolio
Actinomycin DAlbendazoleAmitriptylineAmlodipineAmoxicillin BaseArtemether
Atco Pharma International (Pvt) Ltd holds 231 molecules not in this portfolio
Acetylsalicylic AcidAcyclovirAdapaleneAdapleneAlbuterolAminophylline
Pharmasol (Pvt) Ltd. holds 115 molecules not in this portfolio
AcetazolamideAcyclovirAlpha KetoanaloguesAnastrazoleAnastrozoleAprepitant

Get the full profile for AL-HABIB

This page is a summary. The full company brief adds every registration with its approved ceiling and approval date, per-molecule competitive position, price positioning against the category, and a launch shortlist built from the whitespace above.

Request this brief See what’s included

Company data as of 2026-07-30. Brand and molecule counts from the DRAP registry and observed retail sources.

For medicine intelligence and professional reference only. Not medical advice.